GlassScriptPhysician profile
Gordon K Wolfe
NPI 1649238437
$306.41
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $14.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $139.87 | 2019-2020 | |
| Novo Nordisk INC | $54.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.34 | 2019 | |
| Mylan Specialty L.P. | $13.61 | 2019 | |
| Tactile Systems Technology INC | $13.18 | 2019 | |
| Grifols USA, LLC | $12.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.